A novel approach to oral apoA-I mimetic therapy (vol 54. pg 995, 2013)

被引：5
|
作者：
Chattopadhyay, Arnab
机构：
来源：
JOURNAL OF LIPID RESEARCH | 2013年 / 54卷 / 11期
关键词：
D O I：
10.1194/jlr.M033555ERR
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
引用
收藏
页码：3220 / 3220
页数：1
相关论文
共 50 条
  • [1] A Novel Approach to Oral ApoA-I Mimetic Therapy
    Chattopadhyay, Arnah
    Navab, Mohamad
    Hough, Greg
    Meriwether, David
    Feng, Gao
    Grijalva, Victor
    Springstead, James R.
    Palgunachari, Mayakonda N.
    Namiri-Kalantari, Ryan
    Anantharamaya, G. M.
    Farias-Eisner, Robin
    Reddy, Srinivasa T.
    Fogelman, Alan M.
    CIRCULATION, 2012, 126 (21)
  • [2] A novel approach to oral apoA-I mimetic therapy
    Chattopadhyay, Arnab
    Navab, Mohamad
    Hough, Greg
    Gao, Feng
    Meriwether, David
    Grijalva, Victor
    Springstead, James R.
    Palgnachari, Mayakonda N.
    Namiri-Kalantari, Ryan
    Su, Feng
    Van Lenten, Brian J.
    Wagner, Alan C.
    Anantharamaiah, G. M.
    Farias-Eisener, Robin
    Reddy, Srinivasa T.
    Fogelman, Alan M.
    JOURNAL OF LIPID RESEARCH, 2013, 54 (04) : 995 - 1010
  • [3] Role of the hydrophobic and charged residues in the 218 to 226 region of apoA-I in the biogenesis of HDL (vol 54, pg 3281, 2013)
    Fotakis, Panagiotis
    JOURNAL OF LIPID RESEARCH, 2014, 55 (01) : 163 - 163
  • [4] Oral ApoA-I Mimetic Tg6F Enhances Ezetimibe Amelioration of Dyslipidemia
    Mukherjee, Pallavi
    Hough, Greg
    Chattopadhyay, Arnab
    Reddy, Srinivasa T.
    Navab, Mohamad
    Fogelman, Alan M.
    CIRCULATION, 2016, 134
  • [5] Oral ApoA-I Mimetic Tg6F Enhances Ezetimibe Amelioration of Dyslipidemia
    Mukherjee, Pallavi
    Hough, Greg
    Chattopadhyay, Arnab
    Reddy, Srinivasa T.
    Navab, Mohamad
    Fogelman, Alan M.
    CIRCULATION, 2016, 134
  • [6] Anti-inflammatory apoA-I-mimetic peptides bind oxidized lipids with much higher affinity than human apoA-I (vol 49, pg 2302, 2008)
    Van Lenten, B. J.
    Wagner, A. C.
    Jung, C. L.
    Ruchala, P.
    Waring, A. J.
    Lehrer, R., I
    Watson, A. D.
    Hama, S.
    Navab, M.
    Anantharamaiah, G. M.
    Fogelman, A. M.
    JOURNAL OF LIPID RESEARCH, 2008, 49 (12) : 2698 - 2698
  • [7] A novel apoA-I mimetic peptide suppresses atherosclerosis by promoting physiological HDL function in apoE-/-mice
    Gou, Sanhu
    Wang, Li
    Zhong, Chao
    Chen, Xinyue
    Ouyang, Xu
    Li, Beibei
    Bao, Guangjun
    Liu, Hui
    Zhang, Yun
    Ni, Jingman
    BRITISH JOURNAL OF PHARMACOLOGY, 2020, 177 (20) : 4627 - 4644
  • [8] Improvement of aortic valve stenosis by ApoA-I mimetic therapy is associated with decreased aortic root and valve remodelling in mice
    Trapeaux, J.
    Busseuil, D.
    Shi, Y.
    Nobari, S.
    Shustik, D.
    Mecteau, M.
    El-Hamamsy, I.
    Lebel, M.
    Mongrain, R.
    Rheaume, E.
    Tardif, J-C
    BRITISH JOURNAL OF PHARMACOLOGY, 2013, 169 (07) : 1587 - 1599
  • [9] FAMP, A NOVEL APOA-I MIMETIC PEPTIDE PROMOTES HDL VIA ABCA1-DEPENDENT CHOLESTEROL EFFLUX
    Uehara, Y.
    Ando, S.
    Oniki, K.
    Abe, S.
    Yahiro, E.
    Tanigawa, H.
    Miura, S. -I.
    Saku, K.
    ATHEROSCLEROSIS SUPPLEMENTS, 2010, 11 (02) : 3 - 3
  • [10] Safety, pharmacokinetics, and pharmacodynamics of oral apoA-I mimetic peptide D-4F in high-risk cardiovascular patients
    Bloedon, LeAnne T.
    Dunbar, Richard
    Duffy, Danielle
    Pinell-Salles, Paula
    Norris, Robert
    DeGroot, Bruce J.
    Movva, Rajesh
    Navab, Mohamad
    Fogelman, Alan M.
    Rader, Daniel J.
    JOURNAL OF LIPID RESEARCH, 2008, 49 (06) : 1344 - 1352
12345